PriorNilsson Realinvest vs UBS Lux Equity Fund Biotech USD

PriorNilsson Realinvest vs UBS Lux Equity Fund Biotech USD

1. PriorNilsson Realinvest

  • Security

    PriorNilsson Realinvest A

  • Fee

    1.60%

  • ISIN

    SE0005189537

  • Holdings

    26

2. UBS Lux Equity Fund Biotech USD

  • Security

    UBS Lux Equity Fund Biotech USD P-acc

  • Fee

    2.25%

  • ISIN

    LU0069152568

  • Holdings

    5

Fund Holdings

We have information about 25 holdings in PriorNilsson Realinvest, where the largest holding is Castellum (9.31), followed by John Mattson (9.3) and SCA (9.13). In comparison with UBS Lux Equity Fund Biotech USD, we have 7 holdings where Regeneron Pharmaceuticals is the largest holding (10.04), followed by Moderna (9.21) and Gilead Sciences (4.66).

All Holdings

Here we compare the holdings in PriorNilsson Realinvest and UBS Lux Equity Fund Biotech USD.

PriorNilsson Realinvest UBS Lux Equity Fund Biotech USD
1. Castellum AB
Sweden
9.31 %
1. Regeneron Pharmaceuticals Inc
10.04 %
2. John Mattson Fastighetsföretagen
Sweden
9.3 %
2. Moderna Inc
9.21 %
3. SCA B
Sweden
9.13 %
3. Gilead Sciences Inc
USA
4.66 %
4. Corem Property Group B
Sweden
5.63 %
4. BioNTech SE
4.13 %
5. Wihlborgs Fastigheter AB
Sweden
4.75 %
5. Karuna Therapeutics Inc
3.75 %
6. Nyfosa AB
Sweden
4.38 %
-
7. Stenhus Fastigheter i Norden
Sweden
4.1 %
-
8. Boliden AB
Sweden
3.85 %
-
9. Telia Company AB
Sweden
3.47 %
-
10. Fabege AB
Sweden
3.17 %
-
11. Stora Enso R
Finland
3.15 %
-
12. Aros Bostadsutveckling
3.04 %
-
13. Fast. Balder B
Sweden
2.94 %
-
14. Lundin Mining Corporation
Canada
2.83 %
-
15. NCC B
Sweden
2.6 %
-
16. NP3 Fastigheter Pref
2.36 %
-
17. Pandox B
Sweden
2.2 %
-
18. Diös Fastigheter AB
Sweden
2.11 %
-
19. UPM-Kymmene Oyj
Finland
1.92 %
-
20.
1.92 %
-
21. Train Alliance Sweden B
1.79 %
-
22. Brinova Fastigheter B
1.75 %
-
23. Iberdrola SA
Spain
1.66 %
-
24. Fastighetsbolaget Emilshus B
1.46 %
-
25. Creaspac SPAC
1.13 %
-
26. Peab B
Sweden
0.99 %
-

The list of fund holdings was last updated on September 10, 2025.